CANNAHealthcare Magazine June / July 2017 | Page 19

Endocannadinoid concentrations in hair are associated with PTSD severity.

Wilker S, Pfeiffer A, Elbert T, Ovuga E, Karabatsiakis A, Krumbholz A, Thieme D5, Schelling G, Kolassa IT.

Psychoneuroendocrinology. 2016 May;67:198-206. DOI: 10.1016/j.psyneuen.2016.02.010. E pub 2016 Feb 12.

Neuropsychopharmacology.

2012 Aug;37(9):2132-42. DOI: 10.1038/npp.2012.63. Epub 2012 May 2.

On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment

Stern CA1, Gazarini L, Takahashi RN, Guimarães FS, Bertoglio LJ.

Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (2013) 226:781–792; DOI 10.1007/s00213-012-2955-y

Perhaps most impressive, research by the Department of Pharmacology at the University of Sao Paulo, Brazil shows that CBD works by creating a reconsolidation blockade on new and old trauma memories and, CBD offers lasting results over the studied period of 22 days. While numerous pharmaceuticals also show effectiveness in reconsolidation blockades, only CBD re-balanced the ECS and has no known side effects. And, at the University College London 32 mg of CBD reinforced pathways to extinguish physical fear reactions in 48 adults with no side effects.

The evidence is very strong. CBD is an effective PTSD treatment for regulating fear memory, controlling the stress hormone and restoring the the ECS to homeostasis. CBD from industrial hemp contains no significant amount of THC and is therefore undetectable in drug screenings. CBD should be the standard therapy immediately following traumatic experiences, including head trauma and stroke.

We as medical professionals and researchers must work together to eliminate stigma while continuing research. I provide ongoing CBD training for medical professionals and I am open to research collaboration, please reach out to me with any questions you have regarding CBD.

Bio:

Doctor Blair, M.D.

A West Point and University of Miami medical school graduate, retired Colonel (US Army) Phillip Blair, MD has treated patients on 3 continents, served as a combat physician in the Gulf War, and in his private tele-medicine practice, he treats patients in all 50 US States and 10 countries. He began his post-military career as a disease management specialist which lead him to research cannabidiol (CBD) on behalf of his patients. He has successfully treated patients with conditions ranging from cancer to PTSD with CBD. He is now a respected expert on the endocannabinoid system (ECS). In addition to serving patients through his tele-medicine practice, he is also Chief Medical Advisor for Elixinol where he works directly with patients and medical professionals as well as the product development team.

He can be reached at

[email protected]

THE RESEARCH

19